MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Home・Aktien・Fate Therapeutics Inc

Fate Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

1.16 -2.52

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.12

Max

1.19

Schlüsselkennzahlen
By Trading Economics
Einkommen	-124K -32M
Verkäufe	-372K 1.4M
EPS	-0.27
Gewinnspanne	-2,364.792
Angestellte	161
EBITDA	-13M -42M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+63.93% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	11. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-43M 131M
Vorheriger Eröffnungskurs	3.68
Vorheriger Schlusskurs	1.16

Nachrichtenstimmung

By Acuity

50%

151 / 349 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

0.9101 / 1.14 Unterstützung & Widerstand

Fate Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Apr. 2026, 17:26 UTC

Wichtige Nachrichtenereignisse

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7. Apr. 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7. Apr. 2026, 23:47 UTC

Market Talk

Wichtige Nachrichtenereignisse

Market Talk Roundup: Latest on U.S. Politics

7. Apr. 2026, 23:47 UTC

Market Talk

Wichtige Nachrichtenereignisse

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7. Apr. 2026, 23:44 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7. Apr. 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Apr. 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7. Apr. 2026, 23:37 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7. Apr. 2026, 23:15 UTC

Market Talk

Wichtige Nachrichtenereignisse

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7. Apr. 2026, 23:04 UTC

Wichtige Nachrichtenereignisse

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7. Apr. 2026, 23:04 UTC

Wichtige Nachrichtenereignisse

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7. Apr. 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Apr. 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7. Apr. 2026, 23:01 UTC

Wichtige Nachrichtenereignisse

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7. Apr. 2026, 22:58 UTC

Wichtige Nachrichtenereignisse

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7. Apr. 2026, 21:56 UTC

Akquisitionen, Fusionen, Übernahmen

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

7. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Apr. 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7. Apr. 2026, 19:17 UTC

Wichtige Nachrichtenereignisse

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7. Apr. 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7. Apr. 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7. Apr. 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7. Apr. 2026, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7. Apr. 2026, 18:40 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7. Apr. 2026, 18:39 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7. Apr. 2026, 18:24 UTC

Wichtige Nachrichtenereignisse

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. Apr. 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7. Apr. 2026, 16:21 UTC

Wichtige Nachrichtenereignisse

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. Apr. 2026, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Fate Therapeutics Inc Prognose

Kursziel

By TipRanks

63.93% Vorteil

12-Monats-Prognose

Durchschnitt 2 USD 63.93%

Hoch 2 USD

Tief 2 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Fate Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Fate Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

0.9101 / 1.14Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Stimmung

By Acuity

151 / 349 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.